Brainstorm Cell Therapeutics is a biotechnology company that develops and commercializes autologous cellular therapies for neurodegenerative diseases. Their NurOwn cell therapy platform uses cell culture methods to stimulate stem cells to secrete neurotrophic factors, modulate disease processes, and enhance neurological function. They are currently conducting clinical trials for the treatment of ALS, multiple sclerosis, Alzheimer's, and other neurodegenerative diseases. The company has a manufacturing partnership with Catalent and is headquartered in New York.